ÂÜÀòÂÒÂ×

Mathai Mammen, M.D., Ph.D., serves as the CEO, President, and Chairman of Parabilis Medicines since June 2023, focusing on discovering and developing impactful medicines for patients. Mammen is also a member of the Board of Directors for Kelonia Therapeutics, Xaira Therapeutics, and Sandoz, while holding an Executive Advisor position at General Atlantic and previously contributing to 10x Genomics and Johnson & Johnson. Notably, Mammen was Executive Vice President of Pharmaceuticals and R&D at Johnson & Johnson from June 2017 to February 2023, overseeing significant advancements in the company's pharmaceutical R&D. Mammen's extensive experience includes senior leadership roles at Merck, Theravance Biopharma, and Innoviva, alongside academic credentials from prestigious institutions including Harvard Medical School, Harvard University, MIT, and Dalhousie University.